Background
Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.Methods
A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study...
